Suivi et prise en charge des troubles endocriniens en post-greffe de cellules souches hématopoïétiques : dyslipidémie et thyropathie

Cornillon, Jérôme; Vantyghem, Marie-Christine; Couturier, M.; Berranger, Eva de; François, Sylvie; Hermet, Éric; Maillard, Natacha; Marçais, Ambroise; Tabrizi, Reza; Decanter, Christine; Duléry, Rémy; Bauters, F; Yakoub-Agha, Ibrahim

doi:10.1016/j.patbio.2013.07.010

Cited by 11 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The “low T3 syndrome” was usually asymptomatic, especially in auto-HSCT recipients, and did not require any treatment. Nevertheless, these patients should be monitored every 3 months until their endocrine values do not return into the normal range [103]. However, none of our allo- or auto-HSCT patients developed overt hypothyroidism; the possible explanation can consist in the fact that no one did receive TBI (Figure 1) [27, 90].…”

Section: Hypothalamus-pituitary-thyroid Axismentioning

confidence: 99%

Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells

Orio

Muscogiuri²,

Palomba

et al. 2014

The Scientific World Journal

View full text Add to dashboard Cite

Early and late endocrine disorders are among the most common complications in survivors after hematopoietic allogeneic- (allo-) and autologous- (auto-) stem cell transplant (HSCT). This review summarizes main endocrine disorders reported in literature and observed in our center as consequence of auto- and allo-HSCT and outlines current options for their management. Gonadal impairment has been found early in approximately two-thirds of auto- and allo-HSCT patients: 90–99% of women and 60–90% of men. Dysfunctions of the hypothalamus-pituitary-growth hormone/insulin growth factor-I axis, hypothalamus-pituitary-thyroid axis, and hypothalamus-pituitary-adrenal axis were documented as later complicances, occurring in about 10, 30, and 40–50% of transplanted patients, respectively. Moreover, overt or subclinical thyroid complications (including persistent low-T3 syndrome, chronic thyroiditis, subclinical hypo- or hyperthyroidism, and thyroid carcinoma), gonadal failure, and adrenal insufficiency may persist many years after HSCT. Our analysis further provides evidence that main recognized risk factors for endocrine complications after HSCT are the underlying disease, previous pretransplant therapies, the age at HSCT, gender, total body irradiation, posttransplant derangement of immune system, and in the allogeneic setting, the presence of graft-versus-host disease requiring prolonged steroid treatment. Early identification of endocrine complications can greatly improve the quality of life of long-term survivors after HSCT.

show abstract

Section: Hypothalamus-pituitary-thyroid Axismentioning

confidence: 99%

Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells

Orio

Muscogiuri²,

Palomba

et al. 2014

The Scientific World Journal

View full text Add to dashboard Cite

show abstract

“…Hypogonadism is common after HSCT, with rates as high as 92% for males and 99% for females [1,43]. The degree of dysfunction is dependent on age, gender, pre-transplant therapy, and conditioning regimen [44].…”

Section: Hypogonadismmentioning

confidence: 99%

Managing Endocrine Disorders in Adults After Hematopoietic Stem Cell Transplantation

Matthews¹,

Eplin²,

Savani³

et al. 2019

CHI

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) has become a potentially curative therapy for an increasing number of malignant and non-malignant conditions. As survival rates continue to improve, the focus of patient care has shifted from managing not only immediate but also long-term complications. Endocrine disorders are among the most prevalent late effects following HSCT. Detecting and treating such conditions offer new challenges, as well as opportunities to reduce preventable morbidity and mortality associated with HSCT. Our objective is to summarize recent literature and describe practical approaches to screening for and managing endocrine-related late effects. We focus on dyslipidemia, diabetes, thyroid disorders, osteoporosis, and hypogonadism. Mechanisms, monitoring, and management recommendations for each disorder are outlined. Growing data on these disorders in the post-transplant setting highlight the need for future study and evidence-based guidelines.

show abstract

“…24,[26][27][28] Il est décrit un syndrome métabolique post-transplantation avec une insulinorésistance, un état pro-thrombotique et inflammatoire, une dyslipidémie, une HTA, et une répartition abdominale et viscérale des graisses. 29 Après une allogreffe dans l'enfance, 40 à 50 % des patients devenus adultes souffrent de dyslipidémies et jusqu'à 21 % de diabète. 1 A un an post-greffe, 12 % des enfants ont un index de résistance augmenté sur l'HOMA-IR (Homeostasis Model Assessment-Insulino Resistance), pouvant aller jusqu'à 88% des cas à l'âge adulte en cas de conditionnement avec ICT.…”

unclassified

Conséquences endocriniennes, osseuses et métaboliques des greffes de cellules souches hématopoïétiques allogéniques chez l’adulte

Deméocq

Thuiller

Couturier

et al. 2018

Annales d'Endocrinologie

Self Cite

View full text Add to dashboard Cite

show abstract

Suivi et prise en charge des troubles endocriniens en post-greffe de cellules souches hématopoïétiques : dyslipidémie et thyropathie

Cited by 11 publications

References 10 publications

Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells

Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells

Managing Endocrine Disorders in Adults After Hematopoietic Stem Cell Transplantation

Conséquences endocriniennes, osseuses et métaboliques des greffes de cellules souches hématopoïétiques allogéniques chez l’adulte

Contact Info

Product

Resources

About